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Abstract 
Objective: To determine whether blood flow rate influences circuit life in continuous renal 
replacement therapy. 
Design: Prospective randomized controlled trial. 
Setting: Single centre tertiary level intensive care unit. 
Patients: Critically ill adults requiring continuous renal replacement therapy. 
Interventions: Patients were randomized to receive one of two blood flow rates:150 mL/min or 
250 mL/min. 
Measurements and Main Results: The primary outcome was circuit life measured in hours. 
Circuit and patient data were collected until each circuit clotted or was ceased electively for 
non-clotting reasons. Data for clotted circuits are presented as median (Inter-quartile range) 
and compared using the Mann Whitney U test. Survival probability for clotted circuits was 
compared using log-rank test. Circuit clotting data were analysed for repeated events using 
hazards ratio (HR). One hundred patients were randomised with 96 completing the study (150 
mL/min, n=49; 250 mL/min, n=47) using 462 circuits (245 run at 150 mL/min and 217 run at 
250 mL/min). Median circuit life for 1st circuit (clotted) was similar for both groups (150 mL/min: 
9.1 [5.5, 26] hrs vs. 10 [4.2, 17] hrs; p=0.37). CRRT using blood flow rate set at 250 mL/min was 
not more likely to cause clotting compared to 150 mL/min (HR, 1.00 [0.60, 1.69]; p=0.68). 
Gender, Body Mass Index, weight, vascular access type, length, site, mode of CRRT or 
International Normalised Ratio had no effect on clotting risk. CRRT without anticoagulation was 
more likely to cause clotting compared to use of heparin strategies (HR 1.62, p=0.003). Longer 
Activated Partial Thromboplastin Time (HR 0.98, p=0.002] and decreased platelet count (HR 
1.19 p=0.03] was associated with a reduced likelihood of circuit clotting.  
Conclusions: There was no difference in circuit life whether using blood flow rates of 250 
mL/min or 150 mL/min during CRRT.  
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Introduction 
Acute kidney injury (AKI) is a complication of critical illness that affects up to 50% of 
intensive care patients.1-3 The use of Renal Replacement Therapy (RRT) has evolved as the 
treatment for severe AKI and is required in 5-6% of all critically ill patients in intensive care 
units (ICUs).4  Continuous Renal Replacement Therapies (CRRT) relies on the maintenance of 
extracorporeal circuit (EC) patency for as long as possible, however premature circuit failure 
due to clotting may cause blood loss, reduced therapeutic efficacy and increased workload 
and treatment costs.5-8  
Clogging and clotting of the hemofilter membrane is the major mechanism of 
premature failure and circuit loss in CRRT. 9,10   It has been suggested that increasing blood flow 
rate (BFR) through the EC to speeds greater than 200 mL/min may reduce premature 
clotting.11 One recent report demonstrated a reduction in filter lifespan when BFR was less 
than 200 mL/min concluding that the optimal blood flow rate during CRRT is between 250-
300 mL/min.12  
The impact of BFR on membrane clotting rate is potentially important and has not 
been examined in controlled studies. Despite suggestions to increase blood flow rates in the 
EC11,12, there remains great variability in the prescription of this setting worldwide. Although 
a recent survey of Australian and New Zealand ICUs indicated a BFR of 150-200 mL/min was 
the dominant setting, a faster rate of 200-250 mL/min was also commonplace in ICU’s 
surveyed.13 Observational studies and recent worldwide practice surveys of CRRT also 
demonstrate great variability in practice from 80 mL/min12 to 350 mL/min.14-16  While BFR may 
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be an important determinant of circuit life in CRRT, the most suitable speed to reduce clotting 
and optimise membrane life has not been identified. To address this question, we conducted 
a prospective randomized controlled trial (RCT). We tested the hypothesis that a faster blood 
flow rate (250 mL/min) would be superior to a slower blood flow rate (150 mL/min) in 
maintaining circuit patency in CRRT.  
Materials and Methods 
Trial design and setting 
This study was a prospective, parallel group RCT conducted in a 24 bed, adult, tertiary 
intensive care in Melbourne, Victoria, Australia. The study was registered at the Australian 
New Zealand Clinical Trials Registry (ACTRN:12615001353583) and approved by Austin Health 
Human Research Ethics Committee (HREC project No. H2012/04772). Written informed 
consent was obtained from the patient or their next of kin prior to, or soon after enrolment. 
Eligibility criteria 
Critically ill patients in ICU were eligible for the study if they fulfilled three criteria: 1) 
age ≥ 18 yrs, 2) AKI (RIFLE classification F)16 requiring CRRT and 3) vascular access was via the 
femoral vein for standardisation. Patients were considered ineligible for the study if they 
fulfilled any of the following exclusion criterion: 1) required citrate anticoagulation (citrate 
protocol requires set blood flow rate of 150 mL/min), 2) expected stay in the ICU was less than 
24 hours.  
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Interventions 
The study compared two blood flow rate settings on circuit life in CRRT. The 
intervention was a set BFR of 250 mL/min and the control was a set BFR of 150 mL/min. CRRT 
was performed using Continuous VenoVenous Hemofiltration (CVVH) or Continuous 
VenoVenous Hemodiafiltration (CVVHDF) modalities. Vascular access was via either Niagara 
13.5 Fr-catheter (24cm) (Bard, Murray Hill, NJ, USA) or Gamcath Dolphin Protect 13.0 Fr-
catheter (25 cm) (Gambro, Hechingen, Germany) dual lumen catheters. Treatment modality 
and choice of vascular access was at the discretion of the treating physician. Prismaflex with 
AN69ST (ST100) 1.0 m2 membrane (Gambro Nephral TM, Lund, Sweden) or Infomed HF 440 
with DF 140 Polyethersulfone 1.4 m2 membrane (Infomed, Geneva, Switzerland) was used for 
all treatments. Bicarbonate buffered replacement and dialysis fluid (Baxter, Castlebar, Co. 
Mayo, Ireland) was used. In CVVH, replacement fluid was delivered into the EC before and 
after the filter (pre and post-dilution), with a ratio of 50% predilution and 50% postdilution. 
Dose in CVVH was standardised at 2000 mL/hour. In CVVHDF, the replacement fluid was all 
delivered postdilution. Dose in CVVHDF was standardised at 1000 mL/hour replacement and 
1000 mL/hour dialysate.  
Anticoagulation was provided according to a predefined ICU protocol and mandates 
no anticoagulation in patients at risk of bleeding from a coagulopathy or thrombocytopaenia. 
Options for anticoagulation when used included regional heparinisation with unfractionated 
heparin (1000 IU/hour) delivered prefilter and protamine (10 mgs/hour) delivered in the 
return limb of the EC for reversal of heparin. Unfractionated heparin was used alone and 
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delivered pre-filter at 5-10 IU/kg/hour. CRRT was prescribed by the treating intensivist and 
delivered by ICU nurses. The decision to start or stop CRRT, and determining the reason for 
stopping, was done by ICU doctors and nurses respectively as is usual protocol for the ICU.  
Data collection 
Baseline data relating to age, gender, weight, BMI, source of admission, severity of 
illness (Acute Physiology and Chronic Health Evaluation score II, III; Simplified Acute 
Physiology Score II), diagnostic group, presence of sepsis, mechanical ventilation, 
inotropes/vasopressors, and basic laboratory variables pertaining to renal function was 
collected. 
Outcomes 
The primary outcome was circuit life (measured in hours) and recorded as clotted 
when; 1) Transmembrane pressure across the circuit exceeded 300 mmHg, 2) pre-filter 
pressure > 200 mmHg, 3) visible clot obstructing flow through the circuit and 4) the blood 
pump was unable to rotate due to clot obstruction in the membrane or for ‘elective’ reasons. 
e.g. CT, MRI, surgical intervention or cessation prior to clotting for native renal assessment.  
Sample size 
Without supportive data to inform a power calculation for this study, 100 patients 
were chosen to ensure a sample that was sufficient to reflect usual ICU patient characteristics 
and allow recruitment completion in one year. Patients stayed in the BFR treatment group 
allocated at randomization. The treating physician prescribed the CRRT modality for each 
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patient (CVVH or CVVHDF) which was maintained/retained for all subsequent treatments. All 
circuits used for these patients were included and analysed accordingly.  
Randomization 
Patients were screened and entered the study by ICU clinical staff. Patients were 
randomly assigned with stratification for mode (CVVH or CVVHDF). Once the treating 
physician prescribed CRRT and the mode of therapy, patients were randomized using a web 
based central randomization service. A variable block randomization with parallel allocation 
was used to allocate to each study group (150mL/min vs. 250 mL/min).  
Statistical methods 
The primary outcome (circuit life) was analysed in a two-step process. First analysis: 
this excluded all electively removed or non-clotted circuits from the data. The distribution of 
data for all circuits meeting the defined clotting criteria was then assessed. As expected study 
variables were not normally distributed and non-parametric statistics were used with circuit 
life reported as median and IQR. Circuit life for the two groups (150 mL/min vs. 250 mL/min) 
was compared using Mann-Whitney U-test. Analysis of the two groups was then assessed for 
survival probability and presented graphically using Kaplan-Meier survival plots. A log-rank 
test was used to compare circuit life between the two groups. This analysis was not adjusted 
for any confounding variables. 
Second analysis: included all circuits (clotted and those electively removed). Circuit 
life was analysed using repeated events survival analysis. 7,17 A proportional hazard conditional 
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frailty model17 (an extension of cox regression) was used to test for within patient 
dependence. It was expected that there would be heterogeneity among individual trial 
patients. In addition, individual trial patients may contribute one or multiple circuits. It was 
assumed to be a correlation between an individual trial patient contributing multiple circuits 
and circuit life. The frailty model was used to test event dependence (where the event is a 
clotted circuit) within the trial patients. Event dependence in this study meant that an 
occurrence of one event (time to clotting of the circuit) may make further events (additional 
circuit clotting times) more or less likely. The advantage of this model is that it considers any 
within-cluster correlation of circuit life. Proportions were compared using a chi-square test.  
First analysis was carried out using IMB SPSS statistics for Windows (v2, IBM Corp., 
Armonk, NY). Second analysis was performed using SAS (Enterprise Guide v5.1; SAS Institute 
Inc., Carey, NC).  
Results 
Participants and recruitment 
One hundred patients were randomized between June 2013 and August, 2014. Two 
patients from each group were randomized but did not receive CRRT. The CONSORT diagram 
for patient enrolment is shown in Figure 1. Overall, 96 patients (49 in the 150 mL/min group 
and 47 in the 250 mL/min group) contributed a total of 463 study circuits: 245 in the 150 
mL/min group and 218 in the 250 mL/min group. Median study circuits per patient was four 
(IQR 2, 6) and totalled 8206 CRRT treatment hours.  
  
10 
 
At randomization, patients were similar with respect of age, sex, severity of illness 
scores (APACHE II, III, SAPS II), admission source and diagnosis (Table 1.). There was a nine kg 
difference in patient weight between the two groups (p= 0.03); however, BMI was similar for 
both groups. Pre-randomization renal laboratory variables were also similar for both groups. 
Primary outcomes - Circuit Life 
The first analysis incorporated 369 defined clotted circuits. The median circuit life for 
these circuits (n=369) was similar for both groups (150 mL/min, n=196 [10 hrs IQR 6.0, 24]) 
vs. (250 mL/min, n = 173 [11.5 hrs IQR 6.8, 18.3] p = 0.81). For first analysis, there were 81 
clotted first circuits. The median circuit life of these circuits was 9.1 hrs (IQR, 5.5, 26 hr) in the 
150 mL/min group compared to 10 hrs (IQR, 4.2, 17 hr) in the 250 mL/min group, p=0.37. 
Second and third median circuit lives for those deemed to have clotted were also similar 
(Table 2). The probability of the first study circuit from each patient failing due to clotting did 
not differ between BFR groups (150 ml/min vs. 250 mL/min; HR, 0.85, log rank test = 0.46) 
(Figure 2).  
The second analysis involved evaluation of all circuit terminations (clotted and 
electively removed) and revealed that a BFR of 250 mL/min was not more likely to cause 
clotting compared to 150 mL/min (HR, 1.00 [0.60, 1.69]; p=0.68, variance of the random 
effect, 1.078 [0.23]) (Table 3). There were no differences in likelihood of clotting for:  gender, 
BMI, weight, vascular access type, length or site, mode of CRRT or INR. CRRT without use of 
anticoagulation was more likely to cause clotting compared to use of heparin or 
heparin/protamine (HR 1.62, [1.18, 2.23], p=0.003). Longer APTT (HR 0.98, [0.97, 0.99], 
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p=0.002) was associated with a lower likelihood of circuit clotting. Probability of clotting was 
higher in those patients with higher platelet counts (HR 1.19, [1.01, 1.40], p=0.03) (Table 3).  
Discussion 
This is the first known prospective study to examine the effect of blood flow rate on 
circuit duration in both CVVH and CVVHDF. In a cohort of 100 ICU patients requiring CRRT 
three key findings have been identified: first, when blood flow rate is increased to 250 mL/min 
it does not increase circuit life during CRRT. Second, the use of an anticoagulation strategy and 
longer APTT’s extends CRRT circuit life. Third, patients with higher platelet counts were more 
prone to premature circuit clotting in this study.  
Relationship to previous studies 
The maintenance of circuit patency by prevention of clotting is the greatest challenge 
associated with providing CRRT for critically ill patients. As a result, many studies have focused 
on anticoagulation strategies to extend circuit life,7,18-27 while many aspects of treatment and 
prescription setting have not been investigated. One RCT has included blood flow rate in the 
assessment of circuit clotting in CRRT, indicating that blood flow rates >125 mL/min did not 
improve circuit survival.28 This study was conducted in CVVHD mode which is rarely used in 
current practice.13,15,29,30 Pure diffusive modes of hemofiltration such as CVVHD have been 
shown to be associated with decreased procoagulatory activity in the dialyser membrane 
when compared to convective modes31,32 and makes comparisons to CVVH and CVVHDF 
problematic.  
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One single centre study assessing 1332 treatments from 355 patients concluded that 
BFR did indeed affect circuit life.12 In this retrospective audit, the authors suggest a BFR less 
than 200 mL/min significantly decreased circuit life compared to rates greater than 200 
mL/min. They also determined that BFR greater than 300 mL/min led to lower median circuit 
lives and recommended an optimal BFR of between 250-300 mL/min.  
Implications of study findings 
 Our data provides evidence to suggest that a faster blood flow rate does not influence 
circuit life and prescription of rates greater than 150 mL/min makes no difference to the 
likelihood of clotting in either CVVH or CVVHDF. It has previously been suggested that blood 
flow should be maintained at 200 mL/min33-35 and always be greater than 100 mL/min to avoid 
premature clotting.36 The ability to maintain consistent and constant flow may be more 
critical, with the flow and resistance balance being more important.  We have previously 
reported these mechanical factors and their adverse effect on circuit life.10,37,38  
               Despite many authors suggesting blood flow rates for CRRT of 200-250 mL/min12,33-35 
and international surveys indicating practical prescriptions of >200 mL/min; there has been 
no endorsements for this setting. The Acute Dialysis Quality Initiative (ADQI) consensus 
guidelines for operational characteristics from 2002 indicate that blood flow may be increased 
to augment solute clearance but do not include a recommendation for this prescription.39 The 
more recent Kidney Disease Improving Global Outcomes (KDIGO) consensus guidelines 
outline settings for different RRT modalities indicating 150-250 mL/min is typically prescribed 
for CRRT modes such as CVVH and CVVHDF but make no recommendations for practice based 
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on evidence.40  
The use of anticoagulants to prevent extracorporeal clotting and extend circuit life in 
CRRT has been used for decades.41 Unfractionated heparin (UFH) remains the most commonly 
prescribed anticoagulant13,42 worldwide and remains the standard against which other 
anticoagulant regimens are compared.7,21,22,24,25,43. A regional heparin technique favours 
patient safety and anticoagulant free CRRT is used for a high risk of bleeding.44,45  
We have previously reported on circuit life in CVVH when no anticoagulation was used 
compared to low dose UFH and a regional heparin technique.45 This study of 300 filters 
described similar circuit lives for all three methods and has similarities to our findings which 
indicate the strong association between higher platelet counts and premature circuit clotting.  
Strengths and Limitations 
This RCT of 100 patients presents for the first time the outcomes of an investigation 
into the effect of blood flow rate on circuit life in two commonly used modes of CRRT. This 
analysis is based on a large number of circuits and for 8206 hours of treatment time. This 
number of patients and treatment time is representative of a tertiary level intensive care unit 
and signifies important findings for current CRRT practice. The presentation of our analysis for 
first circuit (clotted) and the analysis of all circuits using repeated events survival analysis 
should be the new standard for studies reporting circuit life in CRRT where previously an all 
circuits analysis may have drawn conclusions not valid due to repeated measures effect. The 
study was not powered to detect a difference as there was insufficient historical data available 
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to make the appropriate group size calculation. One further limitation may be the defined 
blood flow rates used in this study. Blood flow rates less than 150 mL/min or greater than 250 
mL/min may have yielded a different outcome. Circuit life (hrs) in both groups may be shorter 
due to the large proportion of patients enrolled have a diagnosis of liver failure and liver 
transplantation making comparisons to other ICU’s difficult. Two membrane compositions 
were used and anticoagulation according to an established local policy.  These two factors may 
have some influence on our findings. 
Conclusions 
A blood flow rate of 250 mL/min does not improve CRRT circuit life compared with a 
blood flow rate of 150 mL/min. Independent factors that may extend circuit life include 
anticoagulation strategies, higher APTT and lower platelet counts.   
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Figure 1. Flow diagram of participants showing assessment of eligibility, enrollment, treatment allocation and follow-
up in the trial.  CRRT = Continuous Renal Replacement Therapy, CVVH = Continuous VenoVenous Hemofiltration, 
CVVHDF = Continuous VenoVenous Hemodiafiltration 
Figure 2. Kaplan Meier estimate of the probability of continuous renal replacement therapy circuit survival for the first 
circuit – clotted circuits only 
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TABLE 1. Baseline demographic and clinical characteristics  
ADMISSION VARIABLES 150 ML/MIN 
N = 49 
250 ML/MIN 
N = 47 
 
P-VALUE 
    
AGE 61.08 ± 15.96 60.77 ± 18.31 0.93 
    
GENDER (M/F) 34/49 (69%) 24/47 (51%) 0.10 
    
BMI 29.01 ± 5.48 27.59 ± 6.85 0.26 
    
WEIGHT  85.19 ± 20.39 75.85 ± 20.30 0.03 
    
APACHE II 22.16 ± 6.47 23.13 ± 6.55 0.47 
    
APACHE III 85.65 ± 23.17 87.21 ± 26.28 0.76 
    
SAPS II 56.22 ± 14.19 55.55 ± 15.21 0.82 
    
SOURCE OF ADMISSION - NO. /TOTAL    
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NO. (%) 
    
ED 13 (27.7%) 12 (25.5%)  
WARD 17 (34.7%) 17 (36.2%)  
POST OP (ELECTIVE) 7 (14.3%) 6 (12.8%)  
POST OP (EMERGENCY) 5 (10.2%) 4 (8.5%)  
TRANSFER OTHER ICU 5 (10.2%) 5 (10.6%)  
TRANSFER OTHER HOSPITAL 2 (4.1%) 3 (6.4%)  
    
ADMISSION DIAGNOSIS - NO. /TOTAL 
NO. (%) 
   
CARDIOVASCULAR  6 (12.2%) 5 (10.6%)  
CARDIAC SURGERY 11 (22.4%) 8 (17.0%)  
RESPIRATORY 0 1 (2.1%)  
GASTROINTESTINAL 6 (12.2%) 6 (12.8%)  
LIVER FAILURE 5 (10.2%) 6 (12.8%)  
LIVER TRANSPLANT 10 (20.4%) 13 (27.7%)  
ACUTE RENAL/GENITOURINARY 5 (10.2%) 5 (10.6%)  
HEMATALOGICAL 4 (8.2%) 1 (2.1%)  
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INFECTION/ABSCESS 2 (4.1%) 2 (4.3%)  
    
MECHANICAL VENTILATION – NO. (%) 41 (83.7%) 36 (76.6%) 0.44 
    
VASOPRESSOR/INOTROPE – NO. (%) 41 (83.7%) 41 (87.2%) 0.77 
    
SEVERE SEPSIS – NO. (%) 24/49 (49%) 26/47 (55.3%) 0.55 
    
LAB DATA PRIOR TO RANDOMISATION    
SERUM CREATININE 317.20 ± 171.61 297 ± 181.54 0.16 
SERUM UREA 23.62 ± 14.94 21.19 ± 10.03 0.33 
Independent T-test and chi-square test 
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TABLE 2. Circuit life duration – Clotted circuits only 
 
CIRCUIT LIFE  
  
150 ML/MIN 
N = 49 
250 ML/MIN 
N = 47 
 
P-VALUE 
    
ALL CIRCUITS  n = 196 n = 173  
MEDIAN HRS (IQR) 10 (6, 24) 11.5 (6.8, 18.3) 0.81 
    
1ST CIRCUIT  n = 49 n = 47  
MEDIAN HRS (IQR) 9.1 (5.5, 26) 10 (4.2, 17) 0.37 
    
2ND CIRCUIT  n = 35 n = 38  
MEDIAN HRS (IQR) 14 (8.5, 21) 13.8 (8.5, 16.7) 0.45 
    
3RD CIRCUIT  n = 22 n = 23  
MEDIAN HRS (IQR) 17 (10.5, 28.5) 16 (12, 21.5) 0.52 
    
    
Mann Whitney U test 
  
  
26 
 
TABLE 3. Univariate and Multivariate analysis for all circuits 
  UNIVARIATE MODEL MULTIVARIATE MODEL 
COVARIATE Effect HR 
(95% CI) 
 
p-
value 
Random 
Effect 
Variance (sd) 
HR 
(95% CI) 
 
p-
value 
Random 
Effect 
Variance (sd) 
        
BLOOD FLOW 250 mL/min vs. 150 mL/min 1.04 (0.65,1.69) 0.38 1.005 (0.20) 1.00 (0.60, 1.69) 0.68 1.078 (0.23) 
        
GENDER  Male vs. Female 1.56 (0.97, 
2.52) 
0.07 0.905 (0.19) 1.76 (0.93, 3.33) 0.08  
        
BMI  1.02 (0.98, 
1.06) 
0.26 0.979 (0.20) 1.04 (0.95, 1.14) 0.42  
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WEIGHT  for every 5kg increase 1.04 (0.98, 
1.11) 
0.19 0.957 (0.20) 0.96 (0.82, 1.12) 0.59  
        
VASCATH SITE Right Femoral vs. Left femoral 0.75 (0.55, 
1.03) 
0.07 1.075 (0.22) 0.94 (0.66, 1.34) 0.73  
        
VASCATH LENGTH 20 cm vs. 15 cm 0.83 (0.31, 
2.19) 
0.10 1.091 (0.22) 0.92 (0.34, 2.50) 0.18  
 24 cm vs. 15 cm 0.53 (0.22, 
1.27) 
    0.17 (0.03, 1.16)   
        
VASCATH DIAMETER 13 Fr vs. 13.5 Fr 1.41 (0.96, 
2.09) 
0.08 1.055 (0.21) 2.66 (0.24, 29.91) 0.43  
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CRRT MODE CVVHDF vs. CVVH 1.10 (0.68, 
1.77) 
0.70 0.993 (0.20)    
        
ANTICOAGULATION None vs. Heparin/regional 
heparin 
1.65 (1.21, 
2.24) 
0.001 1.148 (0.23) 1.62 (1.18, 2.23) 0.003  
        
PLATELETS (X 1011)  1.13 (0.97, 
1.31) 
0.11 0.928 (0.19) 1.19 (1.01, 1.40) 0.03  
        
INR (RATIO)  0.84 (0.65, 
1.09) 
0.19 0.993 (0.20) 1.05 (0.77, 1.42) 0.77  
        
APTT (SECONDS)  0.98 (0.97, 
0.99) 
0.0003 0.898 (0.19) 0.98 (0.97, 0.99) 0.002  
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